Literature DB >> 3546154

Efficacy of ofloxacin in uncomplicated gonorrhoea.

C Ariyarit, K Panikabutra, A Chitwarakorn, C Wongba, A Buatiang.   

Abstract

A randomised double blind trial comparing single oral dose therapy with 200 mg and 400 mg of ofloxacin, respectively was conducted at the Bangrak Hospital, Bangkok during the period December 6, 1985 to January 24, 1986. We treated 234 male patients diagnosed as having uncomplicated gonococcal urethritis with ofloxacin. Ofloxacin, at a single dose of 200 mg or 400 mg, was given to each of them. Fourteen patients were excluded for efficacy assessment. There were 223 patients left for safety assessment. The cure rates were 100% in both groups. Among 233 isolates tested, 48.5% were penicillinase producing Neisseria gonorrhoeae. The range of minimum inhibitory concentrations of ofloxacin was 0.008 to 0.063 mg/l. No adverse drug experiences were reported.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3546154     DOI: 10.1007/BF01661304

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  National gonorrhea therapy monitoring study: in vitro antibiotic susceptibility and its correlation with treatment results.

Authors:  H W Jaffe; J W Biddle; C Thornsberry; R E Johnson; R E Kaufman; G H Reynolds; P J Wiesner
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

2.  Neisseria gonorrhoeae and gonococcal infections.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1978

3.  Sensitivity to penicillin, thiamphenicol, kanamycin, cefoxitin and spectinomycin of penicillinase-producing Neisseria gonorrhoeae (PPNG) in Bangkok. Relation to the results of treatment.

Authors:  K Panikabutra; C Ariyarit; A Chitwarakorn; T Warnnissorn; C Saensanoh
Journal:  J Med Assoc Thai       Date:  1982-06

4.  Cefotaxime in the treatment of gonorrhoea caused by penicillinase producing N. gonorrhoeae (PPNG) and non penicillinase producing N. gonorrhoeae (Non PPNG).

Authors:  K Panikabutra; C Ariyarit; A Chitwarakorn; T Warnisorn
Journal:  J Med Assoc Thai       Date:  1982-05

5.  Results of the treatment of uncomplicated gonorrhoea in the male with four different schedules.

Authors:  K Panikabutra
Journal:  J Med Assoc Thai       Date:  1978-05

6.  National gonorrhea therapy monitoring study: treatment results.

Authors:  R E Kaufman; R E Johnson; H W Jaffe; C Thornsberry; G H Reynolds; P J Wiesner
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

7.  HR 756--a new cephalosporin in the treatment of gonorrhoea caused by ordinary and penicillinase-producing strains of Neisseria gonorrhoeae.

Authors:  V S Rajan; E H Sng; R Pang; N J Tan; T Thirumoorthy; K L Yeo
Journal:  Br J Vener Dis       Date:  1980-08

8.  Ceftriaxone in the treatment of ordinary and penicillinase-producing strains of Neisseria gonorrhoeae.

Authors:  V S Rajan; E H Sng; T Thirumoorthy; C L Goh
Journal:  Br J Vener Dis       Date:  1982-10

9.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  Randomised comparative study of ceftriaxone and spectinomycin in gonorrhoea.

Authors:  K Panikabutra; C Ariyarit; A Chitwarakorn; C Saensanoh; C Wongba
Journal:  Genitourin Med       Date:  1985-04
View more
  3 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 3.  The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia.

Authors:  A Sivayathorn
Journal:  Drugs       Date:  1995       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.